Xoma (XOMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $104.00 price target.
Joseph Pantginis has given his Buy rating due to a combination of factors including Xoma’s strong financial position and strategic growth initiatives. Despite a discrepancy between the company’s reported GAAP EPS and the analyst’s estimates, Xoma ended the year with a robust cash reserve of $106.8 million. This financial strength is complemented by growing revenues from royalties and milestones, which are supported by strategic acquisitions and transactions aimed at expanding their royalty portfolio.
Additionally, Xoma’s diverse portfolio provides a buffer against potential negative news from partnered programs, reducing the risk of significant share price declines. The company has several key revenue drivers, such as Vabysmo, Ojemda, and Miplyffa, which contribute to its revenue growth. Furthermore, upcoming catalysts, including Phase 3 results for Ersodetug and Seralutinib, as well as other pipeline developments, present potential upside opportunities for the company. These factors collectively underpin Pantginis’s positive outlook on Xoma’s stock.
In another report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $55.00 price target.